



# Biotech Daily

Monday September 30, 2013

*Daily news on ASX-listed biotechnology companies*

- \* ASX, BIOTECH DOWN: COMPUMEDICS UP 9.5%; PHYLOGICA DOWN 10%**
- \* USPTO BACKS GENETIC TECHNOLOGIES PATENT; MERIAL CHALLENGE**
- \* PERPETUAL SELLS 26m RESMED SHARES, DOWN TO 6%**
- \* CELL SIGNALS REDUCES, DILUTED BELOW 5% OF CELLMID**

## MARKET REPORT

The Australian stock market fell 1.66 percent on Monday September 30, 2013 with the S&P ASX 200 down 88.2 points to 5,218.9 points.

Eight of the Biotech Daily Top 40 stocks were up, 24 fell, three traded unchanged and five were untraded. All three Big Caps fell.

Compumedics was the best, up 0.7 cents or 9.5 percent to 8.1 cents with 100,000 shares traded.

Optiscan and Reva climbed more than six percent; Bionomics was up 4.5 percent; Alchemia was up 3.4 percent; Atcor rose 2.7 percent; with Genetic Technologies and Starpharma up one percent or more.

Phylogica led the falls, down 0.2 cents or 10 percent to 1.8 cents with 61,329 shares traded.

Patrys and Prana lost more than nine percent; Pharmaxis fell 7.1 percent; Antisense and Cellmid were down more than six percent; Benitec, IDT and Neuren lost five percent or more; Medical Developments, Tissue Therapies and Universal Biosensors fell more than four percent; GI Dynamics, Nanosonics, QRX and Viralytics were down three percent or more; Allied Health, CSL, Living Cell, Osprey and Prima shed more than two percent; Cochlear and Phosphagenics were down more than one percent; with Acrux, Mesoblast, Resmed and Sirtex down by less than one percent.

## GENETIC TECHNOLOGIES

Genetic Technologies says the US Patent and Trademark Office has provided an ex-parte re-examination certificate confirming its non-coding DAN patent claims.

Genetic Technologies said the certificate related to the Duluth, Georgia-based Merial LLC request for ex-parte re-examination of claims 1-18 and 26-32 of the US patent (Number 5,612,179) entitled 'Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes'.

The company said the USPTO determined that the patentability of claims 1-18 and 26-32 was confirmed and no amendments had been made to the '179 patent.

Genetic Technologies chief executive officer Alison Mew said the "successful resolution of this, the third re-examination of one of our key patents, reinforces the strength of the company's non-coding patent portfolio".

"With the removal of what some potential licencees have apparently used as a reason to delay settlement discussions, we hope that such negotiations will now resume in earnest, with further licenses to our technology then being granted," Ms Mew said.

Genetic Technologies said it noted that on September 5, 2013, Merial filed another request with the USPTO for re-examination of the '179 patent, which was currently under review by the USPTO.

Genetic Technologies was up 0.1 cents or 1.3 percent to 7.9 cents.

## RESMED

Perpetual and its subsidiaries have reduced their substantial shareholding in Resmed from 115,288,759 shares (7.41%) to 89,040,834 shares (6.27%).

The substantial shareholder notice said that Perpetual bought and sold shares in a large number of trades, from March 13 to September 25 at prices ranging from \$4.16 to \$5.75. In March, Perpetual and its subsidiaries increased their holding in Resmed by 16,158,365 shares to 7.41 percent in more than 400 separate trades at prices ranging from \$4.16 to \$4.39 (BD: Mar 15, 2013).

Resmed fell four cents or 0.7 percent to \$5.65 with 3.5 million shares traded.

## CELLMID

Cell Signals Inc has reduced its substantial holding in Cellmid and been diluted through a series of share issues from 29,000,000 shares (6.80%) to 28,500,000 shares (4.78%).

The Yokohama, Japan-based Cell Signals said that on June 4, 2012 it sold 500,000 shares at 1.4 cents a share.

Cellmid fell 0.2 cents or 6.9 percent to 2.7 cents with 3.3 million shares traded.